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ABSTRACT
This study was conducted to assess optic nerve and peripapillary retinal nerve fibre layer (RNFL) changes in
patients with idiopathic Parkinson’s disease (PD) and its correlation with disease duration and severity. Optic
nerve parameters and RNFL thickness were measured in 24 PD patients and 25 age–gender-matched controls
by Heidelberg Retinal Tomography II (Heidelberg Engineering, Dossenheim, Germany). Patients with visual
acuity below 20/25 were excluded. The mean RNFL in the temporal sector was significantly thinner in the
study group than the control group (p¼ 0.020). Additionally, disease severity and duration negatively
correlated with optic disc parameters in some sectors.
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INTRODUCTION
Idiopathic Parkinson’s Disease (PD) is a common
neurodegenerative disease characterised by loss of
dopaminergic neurons, mainly in substantia nigra.
A reduction of retinal dopamine concentration
was also reported in PD.1,2 Previously described
visual findings associated with PD are reduced
spatial contrast sensitivity, motion perception
abnormalities, colour deficiency, and visual
hallucinations.3
Recently, changes in the retinal nerve fibre layer
(RNFL) and macular thickness have been documented
in several studies with small sample size, and it has
been proposed that this may be associated with loss of
dopaminergic cells and eventually functional visual
abnormalities in PD.4–8
In this study, we aimed to assess the optic disc and
RNFL in Parkinson’s patients with ‘‘healthy eyes’’.
We, therefore, investigated optic disc rim area,
rim volume and RNFL changes using retinal tomo-
graphy in patients with PD without visual
impairment.
MATERIALS AND METHODS
This prospective study was approved by Ethics
Committee and adhered to the tenets of the
Declaration of Helsinki. The study was conducted in
the Department of Ophthalmology and the
Department of Neurology at Pamukkale University.
The participants were patients with PD and age- and
gender-matched healthy subjects as the control group.
All participants provided informed consent.
All patients and controls underwent detailed
ophthalmic evaluation including best-corrected
visual acuity; colour vision; intraocular pressure
measurement; biomicroscopic anterior segment exam-
ination; and dilated posterior segment examination.
Exclusion criteria were: defective colour vision;
Snellen visual acuity below 20/25; history of glau-
coma; intraocular surgery; optic neuropathy; diabetic
retinopathy; high myopia (44D); or other diseases
which can affect optic nerve function or can prevent
optic nerve imaging were excluded.
All PD patients evaluated at the PD clinic were
invited to participate in this study by the neurologist.
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Eventually 42 PD patients accepted to be evaluated at
the ophthalmology department. Of 42 patients, 18
patients were excluded due to having visual impair-
ment, colour vision defects or co-existing ocular
pathologies even if not affecting vision.
Each patient with PD underwent neurological
examination on the same day and disease severity
was scored based on cognitive disturbances, activities
of daily living, motor features of PD.9 They were also
categorised according to existence of tremor and
postural instability status.
Optic nerve images were taken from the partici-
pants with full pupil dilation in a dim room using
Heidelberg Retinal Tomograph II (HRT-II, Heidelberg
Engineering, Dossenheim, Germany). HRT is a con-
focal laser scanning system which creates a 3-D image
of the optic nerve head and gives information about
the optic nerve and the peripapillary RNFL.
Stereometric parameters were calculated automati-
cally by the software. The values obtained from the
HRT-II scan for the study included optic disc rim area,
rim volume, and RNFL thickness in temporal, super-
otemporal, inferotemporal, nasal, superonasal, and
inferonasal sectors.
Statistical analysis was performed by SPSS statis-
tical software (SPSS 11.0.0 for MS Windows; SPSS Inc.,
Chicago, IL). Descriptive statistics were expressed as
mean SD. Independent samples test and Pearson’s
correlation were used for statistical analysis. A value
of p50.05 was considered significant.
RESULTS
A total of 49 eyes of 49 subjects were enrolled in
the study. Of 49 subjects, 24 had PD and 25 were
healthy controls. The mean age of the patients were
62.3 7.9 (range 47–73) and 60.3 7.6 (range 49–73) in
the PD and control groups, respectively. In the PD
group, 15(62.5%) patients were male and 9(37.5%)
were female, whereas in the control group 14(56%)
subjects were male and 11(44%) were female.
The differences in age and gender between the
groups were not significant (p¼ 0.371 and 0.644,
respectively).
In study group, the mean duration of PD was
4.6 3.2 (2–12) years and the mean score for disease
severity was 16.8 9.0 (6–38); 12 (50%) patients had
tremor and 8 (33.7%) had postural instability. All PD
patients were on treatment including L-DOPA (five
patients), dopamine agonist (five patients), combina-
tion of L-DOPA and dopamine agonist (six patients),
L-DOPA, dopamine agonist and monoamine oxidase
B inhibitor (three patients), L-DOPA and monoamine
oxidase B inhibitor (two patients), L-DOPA and
glutamate agonist (two patients) and monoamine
oxidase B inhibitor and dopamine agonist (one
patient).
Tables 1–3 present the mean and sectoral measure-
ments of rim area, rim volume and RNFL in the
study and control groups. The difference in rim area
and rim volume was not significant between the study
and control group (Tables 1 and 2). The mean RNFL in
the temporal sector was likely to be thicker
in the control group than the study group (p¼ 0.020,
t-test).
In the study group, disease duration negatively
correlated with rim area in temporal sector
(r¼0.440, p¼ 0.036) and rim volume in temporal
sector (r¼0.450, p¼ 0.031) after controlling for the
effect of age. Disease severity negatively correlated
with rim volume for the inferonasal sector (r¼0.479,
p¼ 0.018). Age, having tremor or postural instability
did not significantly correlate with any of the ocular
parameters in patients with PD.
DISCUSSION
In our study, temporal RNFL thickness was signifi-
cantly thinner in patients with PD than that in
controls. Disease duration showed a negative correla-
tion with rim area and volume in the temporal sector
TABLE 1 Comparison of optic disc rim area by retinal




n¼ 25 p Value
Rim area (average, mm2) 1.76 0.42 1.95 0.81 0.298
Rim area temporal sector 0.28 0.10 0.34 0.24 0.296
Rim area superotemporal
sector
0.21 0.04 0.25 0.11 0.149
Rim area inferotemporal
sector
0.23 0.08 0.26 0.12 0.311
Rim area nasal sector 0.48 0.11 0.52 0.18 0.411
Rim area superonasal
sector
0.25 0.05 0.28 0.10 0.180
Rim area inferonasal
sector
0.26 0.07 0.28 0.09 0.451
TABLE 2 Comparison of optic disc rim volume by retinal




n¼ 25 p Value
Rim volume (average, mm3) 0.42 0.19 0.55 0.37 0.162
Rim volume temporal sector 0.02 0.01 0.04 0.06 0.283
Rim volume superotemporal
sector
0.05 0.02 0.07 0.05 0.190
Rim volume inferotemporal
sector
0.05 0.03 0.06 0.06 0.421
Rim volume nasal sector 0.15 0.05 0.16 0.08 0.332
Rim volume superonasal
sector
0.08 0.04 0.09 0.07 0.391
Rim volume inferonasal
sector
0.08 0.04 0.10 0.07 0.191
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whereas disease severity showed a negative correla-
tion with rim volume in the inferonasal sector.
An association between RNFL thickness and PD
was first proposed by Inzelberg et al.4 They showed
that the thickness in the inferior quadrant of peripa-
pillary RNFL was significantly thinner in PD patients
(n¼ 10) than controls using optical coherence tomo-
graphy (OCT) but they did not show any correlation
between RNFL thinning and disease duration. It is
suggested that dopaminergic loss in the retina might
alter visual processing by modifications of receptive
field properties of ganglion cells and their axons
which form the RNFL.1,4 Reduced dopaminergic
input to a group of ganglion cells might cause
abnormal production of glutamate and atrophy of
these selected fibres.4
Subsequently Yavas et al.,5 reported lower mean
RNFL thickness in patients with PD (n¼ 44) using
HRT with the exception of the temporal and super-
otemporal sectors. Alt|ntas et al.6 assessed the
correlation between retinal findings and clinical
severity in 17 patients with PD. They found that
there was a reduction of RNFL thickness, macular
volume and thickness in patients with PD. Those
parameters did not correlate with the severity or
duration of PD. Similarly, in our study, RNFL did not
correlate with disease duration, however, rim area
and volume in temporal sector showed a significant
negative correlation with disease duration after
adjustment for age.
Hajee et al.7 reported that the inner retina was
significantly thinner in patients with PD (n¼ 24) than
in controls and suggested that PD should be con-
sidered in the differential diagnosis of RNFL thinning.
On the contrary, Aaker et al.8 stated that the
peripapillary RNFL and inner retinal thickness were
not significantly different between PD patients (n¼ 9)
and controls but macular thickness in three of nine
subfields was different from normal values.
Recently, the temporal RNFL was shown to be
thinner on OCT in Parkinson’s patients (n¼ 43)
compared to controls, however, this finding did not
correlate with clinical findings.10 In another study,
Moschos et al.11 reported that the mean inferior and
temporal RNFL thickness was significantly lower in
Parkinson’s patients (n¼ 16) without visual impair-
ment when compared to a control group. Similarly, in
this study, we found that the temporal RNFL was
thinner in patients with PD than controls. The under-
lying mechanism leading to sectoral thinning of the
RNFL is unclear. Loss of the temporal RNFL was
documented in mitochondrial optic neuropathies such
as Leber hereditary optic neuropathy or dominant
optic atrophy; and a mitochondrial pattern has also
been proposed for PD.10,12,13 Temporal RNFL thinning
was also reported in autosomal recessive cone-rod
dystrophy, spinocerebellar ataxia type 1 and multiple
sclerosis.12,14,15 Other than a mitochondrial pattern,
localised breakdown of oxidative defence mechan-
isms and sensitivity of the temporal RNFL to early
damage and subclinical disease activity were also
suggested.12,15 More evidence is needed to under-
stand the mechanism of sectoral thinning of the
RNFL.
In conclusion, the novel finding in our study is that
we found sectoral thinning of the RNFL in patients
with PD with good vision compared to age- and
gender-matched controls. This finding indicates that
axonal degeneration exists in the eye before visual
dysfunction becomes evident in patients with PD. In
future studies the detection of early findings may be
of importance because of advances in protective
treatment modalities which may result in preservation
of structure before the patient becomes symptomatic.
Future studies would show whether retinal or optic
disc imaging will have a place in the care of patients
with PD on a routine basis.
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